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Results a total of 48 patients were enrolled. the 
response rate of the first-line chemotherapy was 49.0 %, 
and the clinical benefit response was 85.1 %. after a 
median of four cycles of chemotherapy, 28 patients 
received surgery (58.3 %). the median PFS and OS of 
all patients were 10.0 and 29.8 months, respectively. 
Patients in the surgery group had much longer PFS (18.1 
vs. 5.6 mo, P = 0.001) and OS (not reached vs. 12.5 mo, 
P = 0.016) compared with those in the non-surgery 
group.
Conclusions For gastric cancer patients with Pan 
involvement, neoadjuvant chemotherapy with XelOX 
demonstrated a good response rate, and a sufficient r0 
resection rate, with acceptable toxicities. Further study is 
needed to confirm the effectiveness of this regimen.
Keywords gastric cancer · Para-aortic lymph node · 
Chemotherapy
Introduction
Despite a decrease in incidence in recent decades, gastric 
cancer is still one of the most common causes of cancer 
deaths of worldwide. In general, gastric cancer patients are 
diagnosed late, with high frequency of nodal involvement 
[1]. In advanced gastric cancer patients who underwent 
radical surgery, the incidence of microscopic metastasis in 
the para-aortic lymph node (Pan) region has been reported 
to range from 10 to 30 % [2]. the Pan region is defined as 
the terminal nodes of the stomach, and termed n3 nodes 
by Japanese Classification of gastric Carcinoma [3], and 
as M1 nodes according to the International Union against 
Cancer (UICC) tumor-node-metastasis (tnM) classifica-
tion [4].
Abstract 
Purpose gastric cancer with para-aortic lymph node 
(Pan) involvement is regarded as advanced disease, and 
only chemotherapy is recommended from the guidelines. 
In unresectable cases, neoadjuvant chemotherapy could 
prolong survival if conversion to resectability could be 
achieved.
Methods the study was a single-arm phase II trial. 
Patients who were diagnosed with gastric cancer and Pan 
involvement (Stations no. 16a2/16b1) were treated with 
capecitabine and oxaliplatin combination chemotherapy 
every 3 weeks for a maximum of six cycles. after every 
two cycles, abdominal computed tomographic scans were 
repeated to evaluate the response, and surgery was per-
formed at the physician’s discretion in patients with suffi-
cient tumor response, followed by chemotherapy with the 
same regimen to complete a total of six cycles. the primary 
end point was the response rate of the preoperative chemo-
therapy. the secondary end points were r0 resection rate, 
progression-free survival (PFS), overall survival (OS), and 
adverse events.
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gastric cancer with Pan metastasis is often unresect-
able and has a poor prognosis even after an r0 resection 
and extensive lymph node dissection. Furthermore, it has 
been reported previously that there is no survival benefit 
from surgery and D2 lymphadenectomy with para-aortic 
node dissection (D2 +PanD). the 5-year overall survival 
(OS) rate was found to be similar in the groups assigned 
to D2 lymphadenectomy alone and D2 +PanD (P = 0.85) 
[5]. the median OS of patients with Pan involvement was 
13.8 months after palliative chemotherapy without surgery 
[6].
Some investigators have reported that potentially cur-
able gastric cancer can be successfully treated with neoad-
juvant chemotherapy [7]. Several chemotherapy regimens 
have been introduced in an attempt to downstage the tumor, 
and prolong survival following by curative resection [8, 9]. 
However, few previous reports have documented chemo-
therapy that enables the curative resection of gastric cancer 
with Pan involvement.
the objective of this study is to determine whether pal-
liative chemotherapy in patients with gastric cancer and 
Pan involvement could make subsequent radical surgery 
feasible and improve OS.
Patients and methods
Patient selection
Patients were enrolled who had gastric or gastroesophageal 
adenocarcinoma proven histologically and Pan metastasis. 
the histological diagnosis was established by upper gas-
trointestinal endoscopic biopsies in all cases. the t-stage 
was determined by endoscopic ultrasonography (eUS), and 
n-stage was determined by abdominal computed tomo-
graphic (Ct) scanning. Chest and pelvis Ct scanning were 
performed to rule out distant metastases. Pan was defined 
as nodes in the region between the upper margin of the 
celiac artery and the upper border of the inferior mesen-
teric artery (Stations no. 16a2/16b1), and with diameters 
>1.0 cm by abdominal Ct scanning. In addition, eligible 
patients were required to have an eastern Cooperative 
Oncology group performance status of 0–1.
Patients were excluded if they had peritoneal gross 
metastasis, lung metastasis, liver metastasis, pleural effu-
sion, other distant metastasis, or serious uncontrolled co-
morbid conditions. Patients who could not comprehend or 
comply with the study were also ineligible. a multidisci-
plinary evaluation was required before a patient’s partici-
pation in this study. all patients signed an approved writ-
ten informed consent form. the protocol of this trial was 
approved by the institutional review board of Zhongshan 
Hospital, Fudan University.
Chemotherapy schedule
Chemotherapy was given as the first-line treatment. the 
regimen of the chemotherapy was as follows: XelOX: 
capecitabine of 1,000 mg/m2 (orally administered twice 
a day on days 1–14) and oxaliplatin at 130 mg/m2 (on 
day 1, as intravenous 2 h boluses). the regimens were 
repeated every 3 weeks after initiation of the first cycle. 
Six cycles were administered during perioperative period, 
or treatment was stopped when disease progression was 
observed.
tumor response and toxicity criteria
after every two cycles, an abdominal Ct scan was per-
formed to evaluate the response. When Pan metastasis 
disappeared or shrank to <1.0 cm, surgery was consid-
ered. If surgery could not be done, chemotherapy would 
be continued until evidence of disease progression 
appeared. If operation could not be done after six cycles 
of chemotherapy, the patients would not have the oppor-
tunity for operation, and the treatment was stopped. the 
response to the treatment was evaluated according to 
response evaluation criteria for solid tumors (reCISt) 
1.1 [10]. Pathological complete response (path Cr) was 
defined as an absence of carcinoma cells in the primary 
site, and pathological partial response (path Pr) was 
defined as <10 % residual carcinoma cells in the speci-
men [11]. adverse events were assessed according to the 
Common toxicity Criteria of the national Cancer Insti-
tute (nCI–CtC) 3.0 [12].
Surgical procedure
a staging laparoscopy was performed to reveal whether 
there were peritoneal metastases in the patients with suffi-
cient response to be considered for subsequent radical sur-
gery. If there was no peritoneal metastasis, radical surgery 
could be done. the type of surgery performed depended on 
the location and extent of the primary cancer. the cancer 
was resected along with a gastric margin of ≥5 cm when 
feasible. For distal cancers, a subtotal gastrectomy was 
considered, and total gastrectomy or total esophagogastrec-
tomy was performed for proximal cancers. an attempt was 
made to perform a D2-type nodal dissection.
Postoperative treatment
after r0 resection, adjuvant chemotherapy with the 
XelOX regimen was initiated within 42 days of surgery, 
and six cycles were administered during perioperative 
period. Patients who could not undergo a radical operation, 
continued original chemotherapy until evidence of disease 
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progression appeared. If patients were confirmed to have 
progressive disease, palliative second-line chemotherapy 
was administered to those patients who could tolerate it. 
adjuvant radiotherapy was not administered after r0 
resection. all enrolled patients were followed up regularly. 
Physical and blood examinations were conducted every 
3 months for the first 3 years and every 6 months thereaf-
ter. an abdominal Ct was performed every 6 months for 
the first 3 years and every year thereafter. Chest Ct and 
upper gastrointestinal endoscopy were conducted every 
year.
Study design and statistical analysis
this trial investigated the efficacy and safety of preopera-
tive XelOX followed by surgery in gastric cancer patients 
with Pan involvement. the primary study end point was 
the response rate. Secondary end points were r0 resec-
tion rate, progression-free survival (PFS), OS, and adverse 
events.
PFS was measured from the date of initial treatment to 
the first objective documentation of disease progression or 
relapse. OS was measured from the start of the treatment 
to the date of the last follow-up or death. In this trial, the 
sample size was 48 cases, which provided 80 % power 
based on the hypothesis as the expected value of 80 %, and 
a threshold value of 65 % in the primary end point using 
one-sided testing at a 10 % significance level. all patients 
were followed up every 3 months. the PFS and OS were 
generated by the Kaplan–Meier method.
Results
Baseline characteristics
From november 2008 to January 2013, 48 patients were 
enrolled in the study. the median age was 63.5 years (range 
from 35 to 77 years). Other baseline characteristics of the 
patients are shown in table 1.
response to the chemotherapy (table 2)
Patients received a median of four cycles of chemotherapy 
regimens. Forty-seven patients had responses ultimately 
(one did not because of acute perforation of stomach 5 days 
after the first regimen of chemotherapy). two persons had a 
complete response (Cr), 21 had partial responses (Pr), 17 
had stable disease (SD), and seven had progression of dis-
ease (PD). the response rate (Cr + Pr) was 49 % (23/47), 
and clinical benefit response (CP + Pr + SD) was 85.1 % 
(40/47). the response evaluations of patients with or with-
out surgery are shown in table 2.
Surgical findings and pathology staging (table 3)
after response evaluation, patients whose Pan metastasis 
disappeared or shrank to <1.0 cm were considered for sur-
gery. a staging laparoscopy was performed first, and three 
patients were diagnosed with peritoneal carcinomatosis. 
Table 1  Baseline characteristics (N = 48)
AEG adenocarcinoma of esophagogastric junction, G gastric cancer
Clinical features N %
gender (N, %)
 Male 41 85.4
 Female 7 14.6
age (median year, range) 63.5 (35–77)
location (N, %)
 aeg 8 16.7
 g 40 83.3
lauren type (N, %)
 Intestinal type 24 50
 Diffuse type 18 37.5
 Mixed type 6 12.5
Cea (N, %)
 normal 22 45.8
 elevated 26 54.2
anemia
 Present (N, %) 37 77.1
Table 2  response evaluation after chemotherapy
a
 One did not have response evaluation because of acute perforation 
of stomach 5 days after the first regimen of chemotherapy and had 
palliative surgery quickly
number of patients (N) %
response evaluation n = 47a
 Cr 2 4.26
 Pr 21 44.68
 SD 17 36.17
 PD 7 14.89
response of patients received 
surgery
n = 28
 Cr 0 0
 Pr 20 71.43
 SD 5 17.86
 PD 2 7.14
 a 1 3.57
response of patients who did not 
receive surgery
n = 20
 Cr 2 10.00
 Pr 1 5.00
 SD 12 60.00
 PD 5 25.00
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then, palliative surgery was provided. at last twenty-eight 
patients received surgery (58.3 %, four had palliative gastrec-
tomy, and 24 had radical gastrectomy and D2 lymphadenec-
tomy), and 20 patients (41.7 %) did not receive operation. In 
the four patients who received palliative surgery, one had 
an acute perforation of stomach, and the other three had 
peritoneal metastases. Second-line treatment was admin-
istered after r2 operation. In the 20 patients who did not 
receive surgery after six cycles of chemotherapy, two had 
Cr, and soon afterward stopped treatment. One had Pr, 
but refused operation, and the original treatment was con-
tinued. twelve had SD, and continued on first-line chem-
otherapy until there was evidence of disease progression. 
Five patients who developed progressive disease did not 
have second-line treatment because of poor performance 
status.
In the operation group, 17 cases (60.71 %) had patho-
logical responses, and three of them had complete patho-
logical responses (10.7 %). the median time from surgery 
to discharge was 9 days (range from 7 to 15 days). Only 
one of the 28 patients had postoperative complications 
described as lung infection after surgery.
Survival
after a median follow-up of 12.4 months (range 3.3–
58.7 mo), 20 patients died, 23 patients had disease progres-
sion, and nine patients relapsed. In the nine patients who 
relapsed, one had lung metastasis, one had liver metastasis, 
two had bone metastases, two had local recurrences, and 
the other three had left supraclavicular lymph node metas-
tases. the median PFS and OS were 10.0 months (Fig. 1) 
and 29.8 months, respectively (Fig. 2). the 1-year PFS rate 
was 47.8 % and 1-year survival rate was 67.9 %. Patients in 
the surgery group had much longer PFS (18.1 vs. 5.6 mo, 
P = 0.001) and OS (not reached vs. 12.5 mo, P = 0.016) 
compared with the non-surgery group (Figs. 3, 4).
toxicity
as shown in table 4, the most common adverse events 
were gastrointestinal issues and leukocytopenia. However, 
only one patient had grade 3 gastrointestinal toxicity and 
Table 3  Surgical findings after chemotherapy
number of patients (N) %
Patients received surgery n = 28
 Surgery type
 radical surgery 24 85.71
 Palliative surgery 4 14.29
Pathological response n = 28
 responders 17 60.71
 non-responders 11 39.30
 pCr 3 10.70
t-stage after surgery n = 28
 yt0 3 10.71
 yt1 2 7.15
 yt2 5 17.86
 yt3 6 21.43
 yt4a 9 32.14
 yt4b 3 10.71
Patients with positive lymph nodes n = 28
 0 8 28.57
 1–2 3 10.71
 3–6 4 14.29
 ≥7 13 46.43
Fig. 1  Progress free survival of all patients (n = 48)
Fig. 2  Overall survival of all patients (n = 48)
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five patients had grade 3 leukopenia. no patients had grade 
4 toxicities. One patient had an acute perforation of stom-
ach 5 days after the first cycle of XelOX regimen. Only 
one of the 28 patients had postoperative complications 
described as lung infection after surgery.
Discussion
Patients with gastric cancers and Pan are currently consid-
ered to have distant metastatic disease and cannot be cured 
by surgery. However, the prognosis and clinical manifes-
tations are somewhat different compared with other sites 
of metastasis. gastric cancer patients with Pan involve-
ment alone were found to have better survival than other 
advanced gastric cancer patients with multiple organ sites 
metastasis [6]. therefore, it did not seem logical to simply 
regard gastric cancer with Pan as M1 disease and receive 
only palliative treatments. We have shown that the survival 
data in patients after palliative chemotherapy who did not 
receive surgery was 12.5 months which is similar to that 
found in other studies [6]. However, in the current study, 
patients who had prior chemotherapy, and subsequent 
radical gastrectomy, had more prolonged survival than the 
patients who could not have operation.
Whether surgery could be done, when surgery should 
be done and what kind of lymph node dissection should 
be done are the most demanding questions in the current 
study. In the current study design, we defined patients 
with Pan metastasis as those who had Pan >1 cm in 
diameter by abdominal Ct scanning as an inclusion cri-
terion. False positive findings may be caused by inflam-
matory lymphadenopathy. Ct criteria for assessing nodal 
metastases are based on nodal size and shape, and the 
presence of central necrosis. nodal size criteria can be 
used when nodes are homogeneous and clearly deline-
ated. the generally used definition of a metastatic lymph 
node depends mostly on a greatest nodal diameter of more 
than 1 cm. With this definition, the correlation with the 
pathological diagnosis has been reported to be close to 
80 % [13]. therefore, when Pan metastasis disappeared 
or shrank to <1.0 cm, radical surgery was considered. 
gastrectomy with D2 lymphadenectomy is the standard 
treatment for curable gastric cancer in eastern asia, and 
outcomes of patients with D2 lymphadenectomy plus 
PanD were not significantly better than those after D2 
lymphadenectomy alone in the patients with metastasis 
at Pan [5]. Sasako et al. reported that compared with 
D2 lymphadenectomy alone, treatment with D2 lym-
phadenectomy plus para-aortic nodal dissection did not 
improve survival rates in curable gastric cancer. gastrec-
tomy with D2 lymphadenectomy is the standard treatment 
for curable gastric cancer in eastern asia. therefore, we 
adopted the D2 lymphadenectomy for all patients without 
para-aortic lymphadectomy. In the current study, in the 
seven patients who relapsed after radical operation, two 
Fig. 3  Progress free survival of surgery group and non-surgery group
Fig. 4  Overall survival of surgery group and non-surgery group
Table 4  toxicities of chemotherapy (N = 48)
toxicities 1 2 3 4
leukocytopenia 14 7 5 0
thrombocytopenia 9 2 2 0
anemia 3 1 1 0
nausea/vomiting 8 5 1 0
Diarrhea 5 3 0 0
Hand-foot skin reaction 12 3 0 0
Hepatic dysfunction 5 0 0 0
neuropathy 10 3 0 0
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had local recurrences, and five had distant metastases to 
lung, bone and left supraclavicular lymph node. none of 
them had Pans involvement, indicating that the gastric 
cancer patients with Pan metastasis could be cured by D2 
lymphadenectomy and neoadjuvant chemotherapy. as the 
patients who received radical surgery had Pan metastasis 
disappear or shrink to <1.0 cm as determined by radio-
logical evaluation before operation, adjuvant radiotherapy 
was not needed after D2 lymphadenectomy,
D2 resection is safe and effective, but the safety of D2 
resection after chemotherapy had not been evaluated. In the 
current study, all 24 patients who received r0 resection had 
a D2 lymphadenectomy. the median time from surgery to 
discharge was 9 days, which is similar to that in patients 
who were not treated with neoadjuvant chemotherapy [14]. 
Despite one trial published by Schuhmacher et al. [15] sug-
gesting a significantly higher risk of mortality after neoad-
juvant chemotherapy, most of the randomized studies did 
not confirm this, as highlighted in a recent meta-analysis 
[16]. In the current study, only one of the 28 patients had 
postoperative complication which was described as a lung 
infection after surgery. D2 lymphadenectomy after preop-
erative chemotherapy is safe and effective.
an existing study showed that patients who benefit-
ted most from neoadjuvant chemotherapy were those who 
achieved a complete response (pCr) with no residual 
microscopic tumor. However, achievement of pCr has been 
reported to be uncommon, occurring in only 10–15 % of 
patients [17], while clinical responses have been reported 
to range from 32 to 42 % [17–20]. In the current study, 
the Cr rate was 10.7 %, and the clinical response rate was 
49 %, which is similar to the results of other studies [17–
20]. three patients had pCr had partial clinical responses 
determined radiologically which indicates that Ct imaging 
results do not always agree with histological findings.
Potentially resectable gastric cancer has been treated by 
several regimens of combination chemotherapy. Due to the 
results of the MagIC trial [7] and real-2 trial [21], epiru-
bicin, cisplatin and 5-Fu (eCF) and epirubicin, cisplatin and 
capecitabine (eOX) are considered to be standard periop-
erative chemotherapy in Western countries. among the vari-
ous combination chemotherapy regimens that are currently 
being investigated to treat advanced gastric cancer, oxali-
platin and capecitabine (XelOX) appears to be useful and 
have encouraging antitumor activity [22]. Phase 2 studies 
have demonstrated that XelOX produces a favorable tumor 
response rate with a relatively mild toxicity profile [23]. the 
current study showed that the regimen of XelOX is safe and 
without severe adverse effects. the limitations of this study 
include small sample size and single research center data.
In conclusion, gastric cancer patients with Pan involve-
ment can benefit from pre-surgical chemotherapy and 
subsequent radical surgery with D2 lymphadenectomy. 
although few advanced gastric cancer patients have Pan 
involvement alone, the current results provide a practi-
cal treatment plan for this special group of patients. large 
scale, multicenter, and randomized trials will help to fur-
ther determine the best treatment strategy for these patients.
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